Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CNTB
Strong SellSinkerConnect Biopharma Holdings Limited · Healthcare · United States · $140M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Connect Biopharma Holdings is a clinical-stage biotechnology company dedicated to developing innovative therapies for chronic inflammatory diseases, primarily in immunology. Its pipeline includes novel small molecule and antibody drug candidates designed to modulate specific immune pathways to address unmet medical needs. The company's future growth hinges on the successful advancement and commercialization of its clinical assets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 26.0M | 64.0K | -99.8% | — | 50.5M | 87.2M | 3591.5% |
| EPS | -2.10 | -1.13 | -0.28 | -1.00 | — | -1.19 | -1.00 | -0.89 | — |
| Shares | 55.0M | 55.1M | 55.3M | 56.4M | +2.5% | 63.0M | — | — | — |
| Debt | 0.4M | 0.5M | 0.2M | 0.7M | 17.0% | 0.6M | — | — | — |
| Equity | 157.5M | 101.5M | 92.2M | 42.0M | -35.6% | — | — | — | — |
| Op CF | -101.5M | -47.7M | -23.6M | -51.2M | — | -60.6M | — | — | — |
| Inv CF | -86.2M | 75.0M | -3.5M | 9.8M | — | — | — | — | — |
| Fin CF | -85.0K | 45.0K | 0.2M | 1.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CNTB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CNTB | Connect Biopharma Holdings Limited(you) | $140M | 10 | Strong Sell |
| UNCY | Unicycive Therapeutics, Inc. | $144M | 12 | Strong Sell |
| VANI | Vivani Medical, Inc. | $128M | 11 | Strong Sell |
| INDP | Indaptus Therapeutics, Inc. | $152M | 13 | Strong Sell |
| KPTI | Karyopharm Therapeutics Inc. | $168M | 11 | Strong Sell |
| HURA | TuHURA Biosciences, Inc. | $134M | 6 | Strong Sell |
| TNYA | Tenaya Therapeutics, Inc. | $155M | 14 | Strong Sell |
| COYA | Coya Therapeutics, Inc. | $108M | 10 | Strong Sell |
| LENZ | LENZ Therapeutics, Inc. | $161M | 14 | Strong Sell |
| CNTN | Canton Strategic Holdings, Inc. | $177M | 8 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%